Nuveen LLC Takes Position in ZimVie Inc. $ZIMV

Nuveen LLC acquired a new stake in ZimVie Inc. (NASDAQ:ZIMV - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 83,423 shares of the company's stock, valued at approximately $901,000. Nuveen LLC owned approximately 0.30% of ZimVie at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ZIMV. Wells Fargo & Company MN boosted its stake in shares of ZimVie by 17.8% during the fourth quarter. Wells Fargo & Company MN now owns 17,037 shares of the company's stock worth $238,000 after buying an additional 2,569 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of ZimVie by 9.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,244,938 shares of the company's stock valued at $17,367,000 after acquiring an additional 107,461 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of ZimVie by 8.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 24,571 shares of the company's stock worth $343,000 after purchasing an additional 1,852 shares in the last quarter. Northern Trust Corp increased its stake in shares of ZimVie by 3.5% during the 4th quarter. Northern Trust Corp now owns 326,252 shares of the company's stock worth $4,551,000 after purchasing an additional 10,988 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in ZimVie in the 4th quarter worth approximately $416,000. Institutional investors and hedge funds own 95.63% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on ZIMV shares. Barclays raised shares of ZimVie from an "underweight" rating to an "equal weight" rating and lifted their target price for the stock from $9.00 to $19.00 in a research note on Tuesday, July 22nd. UBS Group reduced their target price on shares of ZimVie from $16.00 to $10.00 and set a "neutral" rating on the stock in a report on Thursday, May 15th. B. Riley lowered shares of ZimVie from a "buy" rating to a "neutral" rating and set a $19.00 target price on the stock. in a report on Thursday, July 31st. Finally, Wall Street Zen lowered shares of ZimVie from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Four research analysts have rated the stock with a Hold rating, According to data from MarketBeat, ZimVie presently has an average rating of "Hold" and a consensus price target of $17.75.

ZimVie Stock Down 0.2%

NASDAQ:ZIMV traded down $0.03 on Friday, reaching $18.85. The stock had a trading volume of 411,106 shares, compared to its average volume of 328,991. The company has a current ratio of 2.37, a quick ratio of 1.60 and a debt-to-equity ratio of 0.56. The company has a 50-day moving average of $15.81 and a 200 day moving average of $12.11. The stock has a market cap of $531.78 million, a P/E ratio of -26.93 and a beta of 2.19. ZimVie Inc. has a 12-month low of $8.15 and a 12-month high of $19.01.

ZimVie (NASDAQ:ZIMV - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.21 by $0.05. The company had revenue of $116.66 million during the quarter, compared to analysts' expectations of $112.60 million. ZimVie had a negative net margin of 4.39% and a positive return on equity of 6.37%. On average, research analysts predict that ZimVie Inc. will post 0.6 earnings per share for the current year.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.